OR WAIT null SECS
ROCKVILLE, MD, SEATTLE, WA (USA) June 23, 2009
-MEDIFACTS INTERNATIONAL, INC. a leading global cardiovascular core lab announced today the acquisition of the Clinical Trials Services division of Spacelabs Healthcare, Inc. (“CTS”). Financial terms of the transaction were not disclosed.
The combination of Medifacts International and CTS, a global provider of integrated, centralized cardiovascular safety and diagnostic services to the pharmaceutical and biotechnology industries, brings together Medifacts’ industry-leading scientific and regulatory expertise, global logistics and support infrastructure with CTS’ demonstrated commitment to technology, service excellence and client-focused solutions.
Michael Woehler, PhD, President and CEO of Medifacts said: “This combination brings together two highly motivated teams that share a passion for delivering the highest quality service, and creates the broadest product offering of cardiac safety and efficacy services for Phase I through IV clinical trials to pharmaceutical, biotech and medical device manufacturers worldwide. We are delighted to welcome the CTS team into the Medifacts organization today.”
Dr Woehler added, “The combination enhances our existing client relationships and creates an even stronger partner for new and existing clients alike. Medifacts is committed to assisting companies navigate the complex regulatory and scientific requirements throughout the drug development clinical trial process in a fast and cost efficient manner. Our acquisition of the CTS business today is a further demonstration of that commitment.”
John Carpentier, General Manager of CTS commented, “Through the combination with Medifacts, we will be able to provide existing and future clients with a wide array of ECG, Holter, and Blood Pressure technologies supported by the industry's most experienced technologists and scientific experts. I am excited to be joining the Medifacts group and look forward to serving all of our clients as a part of this world class team.”
Driven by best-in-class Science, Technology, and Service Quality, Medifacts International has become a global leader providing ECG, Holter, Ambulatory Blood Pressure Monitoring, Spirometry, Glucometry, Pulse Wave Analysis and related services to pharmaceutical, biotech and medical device companies.
Medifacts International’s scientific expertise, proprietary WebHeart® technology, global presence and recognized quality leadership has established Medifacts as one of the top 3 providers worldwide in comprehensive cardiac safety and efficacy services
About SPACELABS HEALTHCARE, INC.
Spacelabs Healthcare, Inc.
is an international developer, manufacturer and distributor of medical equipment and services including patient monitoring solutions, anesthesia delivery and ventilation systems, diagnostic cardiology solutions and supplies and accessories selling to hospitals, clinics and physicians offices. Additionally, the company provides ECG laboratory services to pharmaceutical companies undertaking clinical trials, whereby patient ECG data is recorded, analyzed, tabulated and interpreted.
The company has established brand names in both medical devices and medical services such as "Spacelabs," "Blease," Del Mar Reynolds and "Dolphin." It employs approximately 1,500 personnel in its offices located in the United States, UK, Canada, France, Germany, Finland, India and Singapore.